Skip to main content

Table 1 Derivation and hypertensive-diabetic subcohort sample characteristics, stratified by incident combined cardiovascular (CV) endpoints

From: Mendelian randomization analysis of vitamin D in the secondary prevention of hypertensive-diabetic subjects: role of facilitating blood pressure control

 

Derivation Subcohort

Hypertensive-Diabetic Subcohort

  
 

(i) N = 1460

Nil incident event

(ii) N = 3185

Incident CV endpoints(iii) N = 561

  

Male [n (%)]

786 (53.8%)

1993 (62.6%)

354 (63.1%)

< 0.001*

0.81

Age (years)

56.2 ± 11.4

64.7 ± 11.5

71.8 ± 10.4

< 0.001*

< 0.001*

Ever smoking [n (%)]

504 (34.5%)

1167 (36.6%)

239 (42.6%)

0.001*

0.007*

Body mass index (kgm-2)

24.0 ± 3.5

25.9 ± 4.1

25.9 ± 4.4

< 0.001*

0.89

Diabetes mellitus [n (%)]

473 (32.4%)

2485 (78.0%)

469 (83.6%)

< 0.001*

0.003*

Systolic blood pressure (mmHg)

120.0 ± 14.8

139.3 ± 19.4

141.4 ± 21.9

< 0.001*

0.031*

Diastolic blood pressure (mmHg)

72.1 ± 8.8

75.5 ± 11.0

70.1 ± 11.3

< 0.001*

< 0.001*

LDL-cholesterol (mmol/L)

3.1 ± 0.9

2.6 ± 0.9

2.5 ± 1.0

< 0.001*

0.077

HDL-cholesterol (mmol/L)

1.4 ± 0.5

1.24 ± 0.44

1.17 ± 0.33

< 0.001*

< 0.001*

Triglycerides (mmol/L)

1.4 ± 1.0

1.6 ± 1.1

1.6 ± 1.2

< 0.001*

0.66

Fasting glucose (mmol/L)

6.8 ± 9.0

7.5 ± 6.3

8.5 ± 10.5

0.001*

0.037*

Creatinine (μmol/L)

79.8 ± 50.1

98.4 ± 74.6

136.6 ± 113.1

< 0.001*

< 0.001*

Lipid-lowering therapy [n (%)]

849 (58.2%)

2254 (70.8%)

452 (80.6%)

< 0.001*

< 0.001*

25-hydroxyvitamin D (Ln) ‡

3.02 ± 0.33

3.01 ± 0.33

2.98 ± 0.38

0.035*

0.043*

Season of recruitment

   

0.57

0.61

 Spring [n (%)]

225 (15.4%)

515 (16.2%)

88 (15.7%)

  

 Summer [n (%)]

478 (32.7%)

940 (29.5%)

178 (31.7%)

  

 Autumn [n (%)]

222 (15.2%)

537 (16.9%)

99 (17.6%)

  

 Winter [n (%)]

535 (36.6%)

1193 (37.5%)

196 (34.9%)

  

Vitamin D GRS ⌞

2.7 ± 1.2

2.7 ± 1.2

2.5 ± 1.3

0.001*

0.002*

  1. *P < 0.05
  2. †P value 1: Group (iii) versus (i)
  3. P value 2: Group (iii) versus (ii)
  4. ‡Natural log-transformed due to skewed distribution
  5. ⌞GRS, genetic risk score (linear 0-6) based on allele scoring summation (CYP2R1: rs2060793; GC: rs4588, rs7041)